Liraglutide (Saxenda) for Weight Loss
Liraglutide Research
8% weight loss
The SCALE trial showed liraglutide 3.0 mg daily produced 8.0% mean weight loss over 56 weeks, the benchmark that semaglutide and tirzepatide have since doubled.
SCALE Obesity and Prediabetes Trial
SCALE Obesity and Prediabetes Trial
View as imageLiraglutide 3.0 mg (brand name Saxenda) was the first GLP-1 receptor agonist approved specifically for weight management, earning FDA approval in December 2014 based on the SCALE clinical trial program. It proved that a peptide hormone analog could produce clinically meaningful weight loss through appetite suppression and delayed gastric emptying. Then semaglutide arrived and roughly doubled the weight loss. Then tirzepatide doubled it again. Liraglutide went from breakthrough to second-tier in less than a decade, a trajectory that tells as much about the speed of peptide drug development as it does about Saxenda's limitations. For the broader context of the liraglutide research program, including its pediatric approvals and where Saxenda fits in 2026, the cluster articles provide detailed perspectives.
Key Takeaways
- The SCALE trial demonstrated 8.0% mean weight loss with liraglutide 3.0 mg daily over 56 weeks, compared to 2.6% with placebo, with 63.2% of patients achieving at least 5% weight loss
- Semaglutide 2.4 mg weekly (Wegovy) produces 15.8% weight loss and tirzepatide 15 mg weekly (Zepbound) produces 20.2%, roughly doubling and tripling liraglutide's efficacy respectively
- The LEADER trial (9,340 patients, median 3.8 years) proved liraglutide reduces major cardiovascular events by 13% in type 2 diabetes patients (Marso et al., NEJM, 2016)
- Liraglutide requires daily subcutaneous injections versus weekly for semaglutide and tirzepatide, creating a convenience disadvantage
- In adolescents aged 12-17, liraglutide reduced BMI standard deviation score by 0.22 compared to placebo, earning FDA approval for pediatric obesity (Danne et al., 2017)
The SCALE Trial Program: Establishing the Benchmark
The SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) program was a series of Phase III trials that established liraglutide 3.0 mg as a weight loss treatment. The landmark SCALE Obesity and Prediabetes trial enrolled 3,731 adults with BMI 30 or greater (or 27 with comorbidities) and randomized them 2:1 to liraglutide 3.0 mg daily or placebo for 56 weeks.
Results at week 56:
- Mean weight loss: -8.0% with liraglutide vs -2.6% with placebo
- Patients achieving 5% or more weight loss: 63.2% vs 27.1%
- Patients achieving 10% or more weight loss: 33.1% vs 10.6%
These numbers were transformative in 2014. No previous FDA-approved weight loss drug had consistently achieved 8% weight loss in large trials. The clinical significance was reinforced by improvements in waist circumference, blood pressure, fasting glucose, and lipid parameters.
Bode (2011) had earlier reviewed liraglutide's pharmacology as the first once-daily GLP-1 receptor agonist, noting its 97% amino acid homology to native human GLP-1 and its 13-hour half-life achieved through albumin binding and resistance to DPP-4 degradation.[1] The weight loss dose (3.0 mg) is twice the diabetes dose (1.8 mg, marketed as Victoza), with the higher dose producing greater appetite suppression.
Why Newer GLP-1s Overtook Liraglutide
The comparison to semaglutide and tirzepatide explains why Saxenda prescriptions have declined:
| Drug | Mechanism | Dose Frequency | Weight Loss | CV Outcome Data |
|---|---|---|---|---|
| Liraglutide 3.0 mg (Saxenda) | GLP-1 agonist | Daily SC injection | ~8% | LEADER: 13% MACE reduction |
| Semaglutide 2.4 mg (Wegovy) | GLP-1 agonist | Weekly SC injection | ~15.8% | SELECT: 20% MACE reduction |
| Tirzepatide 15 mg (Zepbound) | GLP-1/GIP dual agonist | Weekly SC injection | ~20.2% | SURPASS-CVOT: pending |
Three factors drive the difference:
Potency: Semaglutide has higher GLP-1 receptor binding affinity and a longer half-life (168 hours vs 13 hours) due to its C-18 fatty acid chain and albumin binding modifications. This produces more sustained receptor activation. Tirzepatide adds GIP receptor agonism, engaging a second incretin pathway that amplifies weight loss through complementary metabolic effects.
Convenience: Daily versus weekly injections matters for adherence. Liraglutide requires 365 injections per year; semaglutide requires 52. In real-world studies, weekly dosing consistently shows higher persistence rates.
Dose titration: Liraglutide titration from 0.6 mg to 3.0 mg takes 4-5 weeks. Semaglutide titration to the full 2.4 mg dose takes 16-20 weeks but is tolerated better because of the longer intervals between dose increases.
The LEADER Trial: Cardiovascular Safety That Still Matters
The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg or placebo for a median of 3.8 years.[2]
The primary composite outcome (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 13.0% of the liraglutide group versus 14.9% of the placebo group (HR 0.87, 95% CI 0.78-0.97, P=0.01). This 13% relative risk reduction was driven primarily by cardiovascular death (22% reduction) rather than nonfatal events.
LEADER established liraglutide as the first GLP-1 agonist with proven cardiovascular benefit and influenced treatment guidelines worldwide. The SELECT trial later showed semaglutide reduces MACE by 20% in obese patients without diabetes, but LEADER's contribution was establishing the entire GLP-1 class as cardioprotective.
Verma et al. (2022) analyzed the cardiovascular efficacy of liraglutide and semaglutide in patients with diabetes and peripheral artery disease, finding benefits across vascular territories.[3]
Pediatric Evidence
Liraglutide was the first GLP-1 agonist approved for adolescent obesity (ages 12-17). Danne et al. (2017) published the pivotal randomized, double-blind, placebo-controlled trial showing that liraglutide 3.0 mg daily reduced BMI standard deviation score by 0.22 compared to placebo in adolescents with obesity.[4]
Cornejo-Estrada et al. (2023) conducted a systematic review and meta-analysis confirming liraglutide's efficacy in pediatric obesity across available randomized controlled trials.[5] This remains a meaningful niche: while semaglutide has since gained pediatric approvals in some markets, liraglutide has the longest safety track record in adolescents.
Anti-Inflammatory Effects Beyond Weight Loss
Buldak et al. (2024) demonstrated that liraglutide therapy in obese patients alters macrophage phenotype and decreases TNF-alpha production, suggesting anti-inflammatory mechanisms independent of weight loss.[6] This connects to the broader observation that GLP-1 drugs reduce cardiovascular inflammation through direct effects on immune cells rather than solely through metabolic improvement.
Side Effect Profile
The gastrointestinal side effects of liraglutide are common and dose-dependent:
- Nausea: 39-40% (vs 14-15% placebo)
- Diarrhea: 20-21% (vs 10-11% placebo)
- Constipation: 19% (vs 8% placebo)
- Vomiting: 15-16% (vs 4% placebo)
These rates are roughly comparable to semaglutide at equivalent efficacy-adjusted doses. The daily dosing of liraglutide may actually help with GI tolerance: smaller, more frequent receptor stimulation versus the peak-trough pattern of weekly injections. Some patients who cannot tolerate weekly semaglutide do tolerate daily liraglutide, though this has not been formally studied in a head-to-head tolerability trial.
Pancreatitis risk has been monitored across the GLP-1 class. LEADER found no increased pancreatitis risk over 3.8 years of follow-up. Thyroid C-cell tumor risk, observed in rodents with all GLP-1 agonists, has not been confirmed in human epidemiological data.
Where Liraglutide Fits in 2026
Liraglutide occupies a shrinking but defined clinical space:
Cost advantage: generic liraglutide is not yet available, but Saxenda is often cheaper than Wegovy or Zepbound, particularly when insurance coverage varies. In markets where tirzepatide is unavailable or unaffordable, liraglutide remains the accessible option.
Dose flexibility: the daily dosing schedule allows finer dose titration. Patients who experience intolerable side effects at higher doses can maintain a lower dose (2.4 mg or 1.8 mg daily) with proportionally reduced but still meaningful weight loss.
Pediatric indication: liraglutide has the most established pediatric safety and efficacy data of any GLP-1 agonist, making it the default choice for adolescent obesity when pharmacotherapy is indicated.
Cardiovascular proven: LEADER's 3.8-year follow-up provides long-term cardiovascular safety assurance that newer drugs are still accumulating.
Stepping stone: some clinicians use liraglutide as a first-line GLP-1 to establish tolerability before transitioning patients to higher-efficacy weekly agents. This approach has no published evidence supporting it, but reflects clinical practice.
The comparison to liraglutide versus semaglutide and liraglutide's long-term safety are covered in dedicated sibling articles.
Limitations
The SCALE trials were industry-funded (Novo Nordisk), as is typical for drug development programs. The trials used lifestyle modification in both liraglutide and placebo groups, so the 8% weight loss includes diet and exercise effects alongside the drug.
Weight regain after liraglutide discontinuation is substantial. In SCALE extension studies, patients who stopped liraglutide regained approximately two-thirds of their lost weight within one year. This is a class effect of GLP-1 agonists, not specific to liraglutide, but it means the drug requires indefinite use to maintain its benefit.
No head-to-head randomized trial has directly compared liraglutide 3.0 mg to semaglutide 2.4 mg for weight loss. The comparison numbers cited (8% vs 15.8%) come from separate trials with different populations, time points, and designs. A Bayesian network meta-analysis (2026) provides indirect comparison, but direct evidence is lacking.
The Bottom Line
Liraglutide 3.0 mg (Saxenda) was the first GLP-1 receptor agonist approved for weight management, producing 8% weight loss in the SCALE trials. The LEADER trial proved cardiovascular benefit with a 13% reduction in major cardiovascular events over 3.8 years. Liraglutide has been superseded in efficacy by semaglutide (15.8%) and tirzepatide (20.2%) and requires daily rather than weekly injections. It retains relevance for cost-sensitive patients, adolescents, and those who cannot tolerate weekly GLP-1 formulations.